Kinetics of the inhibition of acetylcholinesterase in camel retina by cisplatin

Cancer Letters

Volumn 128, Issue 1, 1998, Pages 79-86

  Al Jafari, Abdulaziz A ^a   Al Khwyter, Fareeda ^a   Kamal, Mohammad A ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Acetylcholinesterase; Camel; Cisplatin; Kinetics; Retina

Indexed keywords

ACETYLCHOLINESTERASE; ACETYLTHIOCHOLINE; CHOLINESTERASE INHIBITOR; CISPLATIN;

ANIMAL TISSUE; ARTICLE; CAMEL; CONTROLLED STUDY; ENZYME INHIBITION; HYDROLYSIS; INHIBITION KINETICS; NONHUMAN; PRIORITY JOURNAL; RETINA;

ACETYLCHOLINESTERASE; ANIMALS; ANTINEOPLASTIC AGENTS; CAMELS; CISPLATIN; ENZYME INHIBITORS; KINETICS; RETINA; TIME FACTORS;

ANIMALIA; CAMELIDAE;

EID: 0032486350     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00054-8     Document Type: Article

References (40)

1. Piura B., Glezerman M., Cohen Y. Experience in the treatment of epithelial ovarian carcinoma with cisplatinum-containing combination chemotherapy and dose intensity calculation. Eur. J. Gynaecol. Oncol. 11:1990;389-393.
2. Einhorn L.H. Combination chemotherapy with cis-dichlorodiammineplatinum (II) in disseminated testicular cancer. Cancer Treat. Rep. 63:1979;1659-1662.
3. Rozencweig M., Von Hoff D.D., Slavik M., Muggia F.M. Cis-diamminedichloroplatinum (II): a new anticancer drug. Ann. Intern. Med. 86:1977;803-812.
4. Von Hoff D.D., Schilsky R., Reichert C.M., Reddick R.L., Rozencweig M., Young R.C., Muggia F.M. Toxic effects of cis-dichlorodiammineplatinum (II) in man. Cancer Treat. Rep. 63:1979;1527-1531.
5. P. Calabresi, B.A. Chabner, in: A.G. Gilman, T.W. Rall, A.S. Nies, P. Taylor (Eds.), The Pharmacological Basis of Therapeutics, Academic Press, New York, 1990, p. 1202.
6. Berenstein A., Wise A., Carr R.E., Ransohoff J. Visual system toxicity following intra-arterial chemotherapy. Neurology. 38:1988;284-289.
7. Eastman A. Interstrand cross-links and sequence specificity in the reaction of cis-dichlorl-(ethylenediamine) platinum (II) with DNA. Biochemistry. 24:1985;5027-5032.
8. Reed E., Yopsa S.H., Zwelling J.R., Ozols R.F., Poirier M.C. Quantitation of cis-diamminedichloroplatinum II (cisplatin) DNA-intrastran adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy. J. Clin. Invest. 77:1986;545-550.
9. A. Rothstein, in: F. Bronner, A. Kleinzeller (Eds.), Current Topics in Membranes and Transport, Academic Press, New York, 1970, p. 135.
10. Lablance G.A., Waxman D.J. Interaction of anticancer drugs with hepatic monooxgenase. Drug Metastasis Rev. 20:1989;395-439.
11. Sadzuka Y., Shoji T., Takino Y. Effect of cisplatin on the activities of enzymes which protect against lipid peroxidation. Biochem. Pharmacol. 43:1992;1872-1875.
12. Al-Jafari A.A. The toxicological effect of cyclophosphamide on acetylcholinesterase activity. Toxicol. Lett. 66:1993;125-131.
13. Al-Jafari A.A., Duhaiman A.S., Kamal M.A. Inhibition of human acetylcholinesterase by cyclophosphamide. Toxicology. 96:1995;1-6.
14. Qayyum M.A., Fatani J.A., El-Badawi M.G. Partial degeneration of autonomic nerves of the heart of methotrexate-treated guinea pigs. Acta Anat. 131:1988;52-55.
15. Marmor M.F. Negative-type electroretinogram from cisplatin toxicity. Doc. Ophthalmol. 84:1993;237-246.
16. Kupersmith M.J., Seiple W.H., Holopigian K., Noble K., Hiesiger E., Warren F. Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Am. J. Ophthalmol. 113:1992;435-438.
17. Ross C.D., Dunning D.D., Juengel L.I., Godfrey D.A. Laminar distribution of choline acetyltransferase and acetylcholinesterase activities in the inner plexiform layer of rat retina. J. Neurochem. 44:1985;1091-1099.
18. Pourcho R.G., Osman K. Acetylcholinesterase localization in cat retina: a comparison with choline acetyltransferase. Exp. Eye Res. 43:1986;585-594.
19. Millar T.J., Ishimoto I., Chubb I.W., Epstein M.L., Johnson C.D. Cholinergic amacrine cells of the chicken retina: a light and electron microscope immunocytochemical study. Neuroscience. 21:1987;725-742.
20. Famiglielli E.V. Jr. 'Starburst' amacrine cells and cholinergic neurons: mirror symmetric ON and OFF amacrine cells of rabbit retina. Brain Res. 261:1983;138-144.
21. Hutchins J.B., Bernake J.M., Jefferson V.E. Acetylcholinesterase in the developing ferret retina. Exp. Eye Res. 60:1995;113-125.
22. Hutchins J.B. Acetylcholine as a neurotransmitter in the vertebrate retina. Exp. Eye Res. 45:1987;1-38.
23. Duhaiman A.S. Purification and some properties of camel lens crystallins. Curr. Eye Res. 7:1988;871-876.
24. Al-Jafari A.A. The nature of the inhibition of camel retina acetylcholinesterase by (EC 3.1.1.7) activity by tetrahydroaminoacridine. J. Ocul. Pharmacol. Ther. 12:1996;503-514.
25. Ellman G.L., Courtney K.D., Andres V. Jr., Featherstone R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 7:1961;88-95.
26. Al-Jafari A.A. Investigation of the reversible inhibition of camel (Camelus dromedarius) acetylcholinesterase by tetracaine. Comp. Biochem. Physiol. 105C(2):1993;323-327.
27. I.H. Segel, Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steadystate Enzyme Systems, Wiley, New York, 1975, pp. 44-50.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Ranadall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1953;265-275.
29. Kamal M.A., Al-Jafari A.A. The preparation and kinetic analysis of multiple forms of human erythrocyte acetylcholinesterase. Prep. Biochem. Biotech. 26:1996;105-119.
30. R.J. Leatherbarrow, GraFit, Version 3.0, Erithacus Software, Staines, 1992.
31. Dixon M. The determination of enzyme inhibitor constant. Biochem. J. 55:1953;170-171.
32. I.H. Segel, Enzyme Kinetics: Behaviour and Analysis of Rapid Equilibrium and Steadystate Enzyme Systems, Wiley, New York, 1975, pp. 136-143.
33. Dawson R. Reversibility of the inhibition of acetylcholinesterase by tacrine. Neurosci. Lett. 11:1990;85-87.
34. Al-Jafari A.A., Kamal M.A., Duhaiman A.S. The mode of inhibition of human erythrocyte membrane-bound acetylcholinesterase by cisplatin in vitro. J. Enzyme Inhib. 8:1995;281-289.
35. 50 with time for the inhibition of human erythrocyte acetylcholinesterase by cisplatin. Cell. Pharmacol. 3:1996;45-48.
36. Grzelinska E., Bartosz G., Bartkowiak A. Aging of the bovine erythrocyte acetylcholinesterase. Enzyme. 30:1983;95-98.
37. Taylor J.L., Mayer R.T., Himel C.M. Conformers of acetylcholinesterase: a mechanism of allosteric control. Mol. Pharmacol. 45:1994;74-83.
38. Patterson T.A., Terry A.V., Kosh J.W. Prevention of physostigmine-, DFP-, and diazinon-induced acute toxicity by monoethylcholine and N-aminodeanol. Br. J. Pharmacol. 97:1989;451-460.
39. Okonek S., Kilbinger H. Determination of acetylcholine, nitrostigmine and acetylcholinesterase activity in four patients with severe nitrostigmine (E 605 forte) intoxication. Arch. Toxicol. 32:1974;97-108.
40. Hodge A.S., Humphrey D.R., Rosenberry T.L. Ambenonium is a rapidly reversible noncovalent inhibitor of acetylcholinesterase with one of the highest known affinities. Mol. Pharmacol. 41:1992;937-942.